HF
TCRX icon

HRT Financial’s TScan Therapeutics TCRX Stock Holding History

HRT Financial’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,581
Closed -$26K – 4706
2025
Q4 		$26K Buy
+26,581
New +$38.5K ﹤0.01% 2960
2025
Q3 		– Sell
-55,369
Closed -$80K – 3656
2025
Q2 		$80K Buy
+55,369
New +$80K ﹤0.01% 2242
2024
Q2 		– Sell
-34,789
Closed -$276K – 3084
2024
Q1 		$276K Buy
+34,789
New +$219K ﹤0.01% 1608
2022
Q1 		– Sell
-20,829
Closed -$93K – 3843
2021
Q4 		$93K Buy
+20,829
New +$150K ﹤0.01% 2777

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

HRT Financial's TCRX Position: Q1 2026 in Review

HRT Financial sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 26,581 shares — an estimated $26K sold.

HRT Financial first reported a position in TCRX in Q4 2021 and held it in 4 quarters. The position peaked at $276K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • HRT Financial reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 26,581 TScan Therapeutics shares in Q1 2026, an estimated $26K.
  • HRT Financial first reported a position in TScan Therapeutics in Q4 2021 and held it in 4 quarters.
  • HRT Financial's TScan Therapeutics position peaked at $276K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.